Acceleron Pharma

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Acceleron Pharma (XLRN) to Report a Decline in Earnings: What to Look Out for

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021. Acceleron expects to report royalty revenue of approximately $25.6

Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to discuss its second quarter 2021 financial results. The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company's website at www.acceleronpharma.com. To participate in the conference call, please dial 833-494-1483 (domestic) or 236-714-2620 (international) and refere

Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021

BioNTech SE

CyberArk Software

Vertex Pharmaceuticals

BJ`s Wholesale Club Holdings Inc

Five9

Talkspace

Wix.com

With the trading day closing in on the halfway point, traders were feeling the heat as all the major indexes were ripping downward.

BioNTech, CyberArk, Vertex Pharma and More Monday Afternoon Analyst Calls

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a Virtual R&D Day for analysts and investors on June 22, 2021. The virtual event will take place from 8:00 a.m. to approximately 11:00 a.m. EDT. Members of the Acceleron leadership team, along with external experts, will review the

Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021

Acceleron Pharma Inc (NASDAQ: XLRN) has announced interim results from the open-label extension of the PULSAR Phase 2 trial evaluating sotatercept in patients with pulmonary arterial hypertension (PAH). The data were presented at the American Thoracic Society 2021 International Conference.

Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented at the American Thoracic Society 2021 International Conference (ATS 2021) preliminary interim data from the SPECTRA Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH). The findings, presented during the session “Cli

Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented at the American Thoracic Society 2021 International Conference (ATS 2021) interim results from the open-label extension of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH). During the ATS 2021 session

Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that multiple abstracts on REBLOZYL® (luspatercept-aamt) will be presented at the upcoming 2021 European Hematology Association (EHA2021) Virtual Congress, to be held from June 9-17. Of particular note, results from the BEYOND Phase 2 trial of lu

Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast on Wednesday, May 19, 2021 at 10:30 a.m. EDT to review updates from the PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH). Data from the PULSAR

Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) Presented at the American Thoracic Society (ATS) 2021 International Conference

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q1 2021 Results - Earnings Call Transcript

Acceleron (XLRN) delivered earnings and revenue surprises of 7.23% and -9.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the first quarter ended March 31, 2021. “Acceleron made significant operational progress during the first quarter,” said Habib Dable, President and Chief Executive Officer of Acceleron. “With the STELLAR Phase 3 trial already

Acceleron Reports First Quarter 2021 Financial Results

Will Acceleron Pharma (XLRN) Report Negative Earnings Next Week? What You Should Know

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $112 million for the first quarter ended March 31, 2021. Acceleron expects to report royalty revenue of approximately $22.4

Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results. The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company's website at www.acceleronpharma.com. To participate in the conference call, please dial 833-494-1483 (domestic) or 236-714-2620 (international) and reference

Acceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021

Acceleron's stock price is near a 52-week high. Reblozyl sales are growing rapidly.

Acceleron: Neutral On Stock Price Gains

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that updates from the PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) will be presented at the American Thoracic Society 2021 International Conference (ATS 2021), held virtually May 1

Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society (ATS) 2021 International Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the New England Journal of Medicine has published results of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH). “We couldn't be more excited that the editors of the New England Journal of Medicine

New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension

Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?

Why Is Acceleron (XLRN) Up 0.5% Since Last Earnings Report?

Acceleron (XLRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Acceleron (XLRN) Stock Jumps 3.3%: Will It Continue to Soar?

Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.

Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q4 2020 Results - Earnings Call Transcript

Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 115.91% year over year to ($0.95), which missed the estimate of ($0.59).

Recap: Acceleron Pharma Q4 Earnings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a very productive year for Acceleron as we generated important results in our lead pulmonary program to advance sotatercept into a registrational Phase 3 tri

News for Acceleron Pharma Stock (XLRN)